Neuroblastoma
Drug research and approvals for neuroblastoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 111 studies of neuroblastoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 25 drug trials for it since 2013, FDA has 3 approved and 43 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 111
- Trials authorized in Canada: 25
- FDA orphan approvals: 3
- EU medicines: 1
- Naxitamab Enabled Transplant-Free Study in High-Risk NeuroblastomaNCT07932808 · Phase 2 · Giselle Sholler · starts Nov 26, 2026
- Prospective Multicenter Study of the Genomic, Transcriptomic, and Biological Profile of Patients With NeuroblastomaNCT07881172 · Not reported · Istituto Giannina Gaslini · starts May 12, 2022
- Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory NeuroblastomaNCT07767630 · Early Phase 1 · Sichuan University · starts Jul 21, 2026
- Dinutuximab-beta and Chemotherapy in Newly Diagnosed High-Risk NeuroblastomaNCT07688252 · Phase 1 · Chang Gung Memorial Hospital · starts Jul 1, 2026
- Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory NeuroblastomaNCT07635056 · Phase 2 · Children's Hospital Medical Center, Cincinnati · starts Dec 1, 2026
- Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic…NCT07584499 · Phase 1 · Sun Yat-sen University · starts May 30, 2026
- A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma PatientsNCT07549321 · Phase 2 / Phase 3 · Renaissance Pharma Ltd. · starts Mar 30, 2026
- Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's…NCT07537400 · Phase 2 · Shaare Zedek Medical Center · starts Jun 23, 2026
- A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory NeuroblastomaNCT07527169 · Phase 2 · M.D. Anderson Cancer Center · starts Oct 1, 2026
Approved 4
- DinutuximabDisialoganglioside GD2 binding agent
- NaxitamabDisialoganglioside GD2 binding agent
- IobenguaneNorepinephrine transporter substrate
- Dinutuximab betaDisialoganglioside GD2 inhibitor
Phase 3 12 of 24
- CyclophosphamideDNA inhibitor
- CarboplatinDNA inhibitor
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- IsotretinoinRetinoic acid receptor agonist
- VincristineTubulin inhibitor
- CisplatinDNA inhibitor
- DoxorubicinDNA topoisomerase II alpha inhibitor
- TemozolomideDNA inhibitor
- IrinotecanDNA topoisomerase I inhibitor
- SargramostimGranulocyte-macrophage colony-stimulating factor receptor agonist
- ThiotepaDNA inhibitor
- TopotecanDNA topoisomerase I inhibitor
Phase 2 12 of 39
- ANTI-GD2 monoclonal antibody 3F8Disialoganglioside GD2 other
- Fludarabine
- VorinostatHistone deacetylase 1 inhibitor
- EflornithineOrnithine decarboxylase inhibitor
- BevacizumabVascular endothelial growth factor A inhibitor
- EMD-273063Disialoganglioside GD2 other
- Fenretinide
- TretinoinRetinoic acid receptor agonist
- RegramostimGranulocyte colony stimulating factor receptor agonist
- CyclosporineCyclophilin A modulator
- MethotrexateDihydrofolate reductase inhibitor
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
Phase 1 or earlier 12 of 44
- LenalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- KetoconazoleCytochrome P450 51 inhibitor
- PegfilgrastimGranulocyte colony stimulating factor receptor agonist
- Zoledronic acidFarnesyl diphosphate synthase inhibitor
- Bortezomib26S proteasome inhibitor
- NivolumabProgrammed cell death protein 1 inhibitor
- RibociclibCyclin-dependent kinase 4 inhibitor
- AlisertibSerine/threonine-protein kinase Aurora-A inhibitor
- TroculeucelEnhanced NK cells
- Edodekin alfa
- Buthionine sulfoximine
- AlemtuzumabCAMPATH-1 antigen inhibitor
How its trials ended
592 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 135 whose ending is known, 24% met their primary endpoint, 9% missed it and 67% stopped early.
- Completed, result not reported24341%
- Ongoing16227%
- Status unknown529%
- Stopped: other or unclear478%
- Met its primary endpoint336%
- Stopped: enrollment or feasibility224%
- Missed its primary endpoint122%
- Stopped: sponsor or business decision112%
- Stopped: lack of efficacy71%
- Stopped: funding31%
| Apr 10, 2026 | A phase 2/3 study to characterize and evaluate the efficacy, safety, and tolerability of hu 14.18k322a treatment given in combination with chemotherapy in…RPL001 / Irinotecan hydrochloride / Temozolomide | Renaissance Pharmaceuticals | Ongoing |
| Jun 19, 2024 | A phase 3 study of dinutuximab added to intensive multimodal therapy for children with newly diagnosed high-risk neuroblastomaUnituxin / Etopophos / Leukine | Childrens Oncology Group | Ongoing |
| Feb 24, 2023 | A phase 1b/2 study of abemaciclib in combination with irinotecan and temozolomide (part a) and abemaciclib in combination with temozolomide (part b) in…Abemaciclib (LY2835219)/ Irinotecan/ Temozolomide/ Dinutuximab/ Sargramostim | Eli Lilly | Closed |
| Sep 2, 2022 | A phase II study of naxitamab added to induction therapy for subjects with newly diagnosed high-risk neuroblastomaNaxitamab / Sargramostim, gm-csf / Ceritinib | Beat Childhood Cancer | Ongoing |
| Jul 4, 2022 | Study of talazoparib for metastatic relapsed neuroblastoma: a pediatric oncology precision medicine studyTalazoparib | C17 Council | Closed |
| Apr 8, 2021 | A multicenter phase 2/3 trial of the efficacy and safety of intracerebroventricular radioimmunotherapy using 131i-omburtamab for neuroblastoma central nervous…131I-omburtamab | Y-mAbs Therapeutics | Closed |
| Feb 25, 2021 | A pilot study of dinutuximab, sargramostim (gm-csf), and isotretinoin in combination with irinotecan and temozolimide in post-consolidation setting for…Irinotecan/ Temozolomide/ Sargramostim | Childrens Oncology Group | Closed |
| Oct 23, 2020 | Pilot study of 68ga-dotatate pet/ct and 123i-mibg scintigraphy imaging of neuroblastoma68GA-dotatate | Centre Hospitalier Universitaire De Sherbrooke | Ongoing |
| Sep 21, 2020 | Phase II trial of eflornithine (DFMO) and etoposide for relapsed/refractory neuroblastomaEflornithine / Etoposide / Etoposide phosphate | Beat Childhood Cancer Research Consortium | Ongoing |
| Sep 10, 2020 | Peds-plan – pediatric precision laboratory advanced: a study using molecular guided therapy with induction chemotherapy followed by a randomized controlled…Eflornithine / Sargramostim | Beat Childhood Cancer Research Consortium | Ongoing |
| Dec 13, 2023 | IwilfinTo reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial… | Uswm, LLC | Approved |
| Nov 25, 2020 | Danyelza®In combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and… | Y-mAbs Therapeutics, Inc. | Approved |
| Mar 10, 2015 | UnituxinFor use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA),… | United Therapeutics Corporation | Approved |
| Aug 13, 2026 | A small molecule degrader of RNA-binding motif protein 39Treatment of neuroblastoma | SEED Therapeutics Inc. | Designated |
| Sep 23, 2025 | DicaprateTreatment of neuroblastoma | Aminex Therapeutics, Inc. | Designated |
| Feb 21, 2025 | A genetically modified salmonella comprising of Diphtheria…Treatment of neuroblastoma | Shanghai Salvectors Biotechnology LTD. | Designated |
| Oct 24, 2024 | PHOX2B PC-CAR T CellsTreatment of neuroblastoma | Hula Therapeutics Inc. | Designated |
| Oct 24, 2024 | SilmitasertibTreatment of neuroblastoma | Senhwa Biosciences, Inc. | Designated |
| Oct 19, 2024 | OpaganibTreatment of neuroblastoma | Apogee Biotechnology Corporation | Designated |
| Aug 21, 2024 | OpaganibTreatment of neuroblastoma | RedHill Biopharma Ltd. | Designated |
| Apr 8, 2024 | Humanized anti-GD2 monoclonal antibodyTreatment of Neuroblastoma | Renaissance Pharma, Ltd. | Designated |
| Feb 26, 2024 | Bispecific anti-GD2/anti-B7-H3 monoclonal antibodyTreatment of Neuroblastoma | Invenra Inc. | Designated |
| Jul 31, 2023 | DTPA[Indium-111]-dinutuximab-IRDye800CWDiagnostic for the management of neuroblastoma | University of Pittsburgh | Designated |
| Nov 25, 2022 | RibociclibTreatment of neuroblastoma | Novartis Pharmaceuticals Corporation | Designated |
| Nov 8, 2022 | 64-fluoro-36-methox-27-methyl-5-thia-4,8-diaza-2(4,6)-tieno[…Treatment of Neuroblastoma | AUM Biosciences | Designated |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| May 8, 2017 | Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron)Dinutuximab beta · orphan | Recordati Netherlands B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA